Assuming study is required, the following results were found.

  • Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress - BioSpace

    a six-month assessment of patients with progressive multiple sclerosis (MS) enrolled in cohort 3 of an ATA188 Phase 1a study, Atara selected this cohort 3 dose to initiate the randomized, double-blind, placebo-controlled Phase 1b part of this study. “We...

    https://mschristian.org/index.php/blog/atara-biotherapeutics-announces-third-quarter-2019-financial-results-and-recent-clinical-operational-and-strategic-progress-biospace
  • Fooling nerve cells into acting normal

    an fatal injury. What exactly signals neurons to keep acting and operating normally has not been known until now. In a new study, scientists at the University of Missouri have discovered that a neuron's own electrical signal, or voltage, can indicate...

    https://mschristian.org/index.php/blog/fooling-nerve-cells-into-acting-normal
  • International MS Genetics Consortium Confirms 233 MS-Related Gene Variations in Largest Study to Date

    September 26, 2019 SUMMARY:The International MS Genetics Consortium (IMSGC) has published the largest MS genetics study to date, analyzing data from 47,429 people with MS and 68,374 individuals without MS.They confirmed 233 variations in the human...

    https://mschristian.org/index.php/blog/international-ms-genetics-consortium-confirms-233-ms-related-gene-variations-in-largest-study-to-date
  • Do minerals play a role in development of multiple sclerosis?

    it. But little was known about whether zinc, iron and other minerals play a role in the development of the disease. A new study shows no link between dietary intake of several minerals and whether people later develop MS. The study is published in the...

    https://mschristian.org/index.php/blog/do-minerals-play-a-role-in-development-of-multiple-sclerosis
  • Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) | Small Molecules | News Channels - PipelineReview.com

    multiple sclerosis (SPMS) in Europe[1])CHMP opinion is based on the Phase III EXPAND trial, the largest randomized clinical study in a broad SPMS patient population (EDSS score 3.0 to 6.5 at baseline), showing Mayzent significantly reduced the risk of...

    https://mschristian.org/index.php/blog/novartis-receives-positive-chmp-opinion-for-mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis-spms-small-molecules-news-channels-pipelinereview-com
  • AJMC® in the Press, September 13, 2019 - AJMC.com Managed Markets Network

    Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press. A study published in this month’s issue ofThe American Journal of Managed Care®(AJMC®) evaluated the patterns of clinical service for long-term nursing...

    https://mschristian.org/index.php/blog/ajmc-in-the-press-september-13-2019-ajmc-com-managed-markets-network
  • Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy | Antibodies | News Channels - PipelineReview.com

    DetailsHits: 97 The primary endpoint of the Phase 2 PASSPORT study was not met, and further development of gosuranemab in progressive supranuclear palsy (PSP) will not be pursued CAMBRIDGE, MA, USA I December 13, 2019 IToday, Biogen Inc. (Nasdaq: BIIB)...

    https://mschristian.org/index.php/blog/biogen-reports-top-line-results-from-phase-2-study-in-progressive-supranuclear-palsy-antibodies-news-channels-pipelinereview-com
  • DOUBT Study Clarifies Role of MRI for TIA or Stroke

    earn free cme credit Earn CME credit by reading this article and completing the posttest. Sign Up Study Authors: Shelagh B. Coutts, Francois Moreau, et al.; Margy E. McCullough-Hicks, Gregory W. Albers Target Audience and Goal Statement: Neurologists,...

    https://mschristian.org/index.php/blog/doubt-study-clarifies-role-of-mri-for-tia-or-stroke
  • Multiple sclerosis drug slows brain shrinkage, study finds

    progressive multiple sclerosis (MS) revealed that ibudilast was better than a placebo in slowing down brain shrinkage. The study also showed that the main side effects of ibudilast were gastrointestinal and headaches. The study was supported by the...

    https://mschristian.org/index.php/blog/multiple-sclerosis-drug-slows-brain-shrinkage-study-finds
  • Does sunlight change our gut microbiome?

    team of researchers, many from the University of British Columbia, in Vancouver, Canada, set out to answer this question by studying how the gut microbiome responds to UV light. When volunteers who were deficient in vitamin D received three sessions of...

    https://mschristian.org/index.php/blog/does-sunlight-change-our-gut-microbiome
  • Common treatment for multiple sclerosis may prolong life

    have found that a widely prescribed drug for multiple sclerosis (MS) is associated with longer survival for patients. The study, published today in the journal Brain, found that people with MS who took a beta interferon drug had a 32 per cent lower...

    https://mschristian.org/index.php/blog/common-treatment-for-multiple-sclerosis-may-prolong-life
  • Could medical marijuana help older people with their ailments?

    lateral sclerosis, Parkinson's disease, neuropathy, spinal cord damage and multiple sclerosis, according to a preliminary study released today that will be presented at the American Academy of Neurology's 71st Annual Meeting in Philadelphia, May 4 to...

    https://mschristian.org/index.php/blog/could-medical-marijuana-help-older-people-with-their-ailments
  • Multiple sclerosis treatments delay progression of the disease

    An international study finds multiple sclerosis treatments have long-term benefits, and that early treatment is important. The Royal Melbourne Hospital and University of Melbourne-led study is the first to provide evidence that the currently available...

    https://mschristian.org/index.php/blog/multiple-sclerosis-treatments-delay-progression-of-the-disease
  • First-in-kind Human 3-dimensional Models of Parkinson's Disease and Progressive Multiple Sclerosis Launching to the International Space Station - Business Wire

    teams from Aspen Neuroscience and the New York Stem Cell Foundation (NYSCF) Research Institute will send a first-in-kind study of neurodegenerative disease to the International Space Station (ISS) on the nineteenth SpaceX Commercial Resupply Services...

    https://mschristian.org/index.php/blog/first-in-kind-human-3-dimensional-models-of-parkinson-s-disease-and-progressive-multiple-sclerosis-launching-to-the-international-space-station-business-wire
  • CMSC INforMS: Use of DMTs Changing ‘Natural History’ of Relapsing MS, Study Says

    to disability since the introduction of disease-modifying treatments (DMTs) some 20 years ago, according to a retrospective study. The study, “Outcomes in a Modern Cohort of Treated Multiple Sclerosis Patients Followed from Diagnosis Up to 15 Years,”...

    https://mschristian.org/index.php/blog/cmsc-informs-use-of-dmts-changing-natural-history-of-relapsing-ms-study-says
  • Study sheds light on brain cell changes in people with MS

    cells found in the brains of people with multiple sclerosis could help develop improved therapies, research has found. The study focused on cells in the brain that help to repair damage to nerve cells caused by the disease. Researchers identified...

    https://mschristian.org/index.php/blog/study-sheds-light-on-brain-cell-changes-in-people-with-ms
  • New app offers faster and easier assessment for multiple sclerosis

    States are living with the disease. MS is most common among women -- three women are diagnosed for every one man. In a study comparing the app, called iCAMS, to a standard, paper-based assessment tool, researchers say they found that the app produced...

    https://mschristian.org/index.php/blog/new-app-offers-faster-and-easier-assessment-for-multiple-sclerosis
  • Higher levels of serotonin after a seizure linked to lower incidence of breathing problems

    to a lower incidence of seizure-related breathing problems called apneas, when a person temporarily stops breathing. The study is published in the September 4, 2019, online issue of Neurology®, the medical journal of the American Academy of Neurology....

    https://mschristian.org/index.php/blog/higher-levels-of-serotonin-after-a-seizure-linked-to-lower-incidence-of-breathing-problems
  • #ECTRIMS2019 - Mayzent's Benefits for MS Patients a 'Key Question,' Says EXPAND's Principal Investigator - Multiple Sclerosis News Today

    the treatment of people with relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS). Data from the EXPAND study (NCT01665144) was one of the key pieces of evidence for Mayzent’s approval. Involving 1,651 patients with SPMS (both active...

    https://mschristian.org/index.php/blog/ectrims2019-mayzent-s-benefits-for-ms-patients-a-key-question-says-expand-s-principal-investigator-multiple-sclerosis-news-today
  • Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years

    serve as a reliable biomarker of disease worsening for patients with multiple sclerosis? Findings In this cohort study of 607 patients with multiple sclerosis, serum neurofilament light chain levels increased significantly faster in those experiencing...

    https://mschristian.org/index.php/blog/association-between-serum-neurofilament-light-chain-levels-and-long-term-disease-course-among-patients-with-multiple-sclerosis-followed-up-for-12-years

Results 1 - 20 of 193
 
 

Follow Us on Twitter

Follow Us On Twitter - Image